Sudarshan Pharma to Raise ₹72 Crore Via Convertible Warrants to Promoters
Sudarshan Pharma will raise up to ₹72 crore by issuing convertible warrants to promoters Hemal Mehta and Sachin Mehta. Shareholder approval will be sought via an EGM.
The fundraising amount is significant and will be utilized for the company's growth, impacting its financial structure and future operations.
The company is raising capital through warrants to promoters, which is a positive step for growth and operational expansion.
Sudarshan Pharma Industries Limited announced that its Board of Directors, in a meeting held on October 29, 2026, approved a proposal to raise funds by issuing and allotting Convertible Warrants. The total amount to be raised will not exceed ₹72,00,00,000 (Rupees Seventy Two Crores only).
Each warrant will be convertible into one equity share of face value ₹1. The issuance will be on a preferential basis to promoters Mr. Hemal Mehta and Mr. Sachin Mehta, in compliance with Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The issue price of the warrants will be determined as per Regulation 164 of the SEBI ICDR Regulations.
The company will seek shareholders' approval for this fund-raising exercise through an Extraordinary General Meeting (EGM), the notice for which will be issued separately. The Board meeting commenced at 7:00 PM and concluded at 10:00 PM on October 29, 2026.
What to do with a filing like this
Sudarshan Pharma Industries Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sudarshan Pharma Industries Limited. Read the original for the full detail.